YAP1 Withdrawal in Hepatoblastoma Drives Therapeutic Differentiation of Tumor Cells to Functional Hepatocyte‐Like Cells-Reference-Cited by-同舟云学术

YAP1 Withdrawal in Hepatoblastoma Drives Therapeutic Differentiation of Tumor Cells to Functional Hepatocyte‐Like Cells

Published:2021-02-08 Issue:3 Volume:73 Page:1011-1027
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Smith Jordan L.¹²,Rodríguez Tomás C.¹²,Mou Haiwei³,Kwan Suet‐Yan¹,Pratt Henry²⁴,Zhang Xiao‐Ou⁴,Cao Yueying¹,Liang Shunqing¹,Ozata Deniz M.¹,Yu Tianxiong⁵,Yin Qiangzong⁶,Hazeltine Max⁷,Weng Zhiping⁴,Sontheimer Erik J.¹⁸⁹,Xue Wen¹⁸⁹¹⁰

Affiliation:

1. RNA Therapeutics Institute University of Massachusetts Medical School Worcester MA

2. Medical Scientist Training Program University of Massachusetts Medical School Worcester MA

3. Cold Spring Harbor Laboratory Cold Spring Harbor NY

4. Program in Bioinformatics and Integrative Biology University of Massachusetts Medical School Worcester MA

5. Department of Bioinformatics School of Life Science and Technology Tongji University Shanghai China

6. Graduate School of Biomedical Sciences University of Massachusetts Medical School Worcester MA

7. Department of Surgery University of Massachusetts Medical School Worcester MA

8. Program in Molecular Medicine University of Massachusetts Medical School Worcester MA

9. Li Weibo Institute for Rare Diseases Research University of Massachusetts Medical School Worcester MA

10. Department of Molecular, Cell and Cancer Biology University of Massachusetts Medical School Worcester MA

Funder

National Institutes of Health

American Cancer Society

National Cancer Institute

Cystic Fibrosis Foundation

Publisher

Wiley

Subject

Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hep.31389

Reference47 articles.

1. Unresectable hepatoblastoma: current perspectives

2. Randomized Comparison of Cisplatin/Vincristine/Fluorouracil and Cisplatin/Continuous Infusion Doxorubicin for Treatment of Pediatric Hepatoblastoma: A Report From the Children’s Cancer Group and the Pediatric Oncology Group

3. Towards an international pediatric liver tumor consensus classification: proceedings of the Los Angeles COG liver tumors symposium

4. Activation of β-Catenin and Yap1 in Human Hepatoblastoma and Induction of Hepatocarcinogenesis in Mice

5. β-Catenin and Yes-Associated Protein 1 Cooperate in Hepatoblastoma Pathogenesis

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of Novel Indole-Based Covalent Inhibitors of TEAD as Potential Antiliver Cancer Agents;Journal of Medicinal Chemistry;2024-09-13

2. Targeting the Hippo/YAP1 signaling pathway in hepatocellular carcinoma: From mechanisms to therapeutic drugs (Review);International Journal of Oncology;2024-07-31

3. Role of Hepatocyte Nuclear Factor 4 Alpha in Liver Cancer;Seminars in Liver Disease;2024-06-20

4. Complex roles of Hippo-YAP/TAZ signaling in hepatocellular carcinoma;Journal of Cancer Research and Clinical Oncology;2023-08-22

5. Genome-wide mapping of cancer dependency genes and genetic modifiers of chemotherapy in high-risk hepatoblastoma;Nature Communications;2023-07-06